To review published literature of levofloxacin 750 mg for the treatment of community-acquired pneumonia (CAP), nosocomial-acquired pneumonia (NAP), and skin and skin-structure infections (SSSI) focusing on microbiology, pharmacokinetic, and pharmacodynamic parameters.
Data Sources
MEDLINE was searched for clinical trials and review articles (1966 to September 2004). Also included were data from the manufacturer. Search terms utilized were levofloxacin, pneumonia, skin infections, adverse effects, pharmacokinetics, pharmacodynamics, and resistance.
Study Selection and Data Extraction
All articles and product labeling regarding levofloxacin for the treatment of CAP, NAP, and SSSI were included for review.
Data Synthesis
Compared with the other currently marketed fluoroquinolones, levofloxacin demonstrates similar in vitro activity to a number of commonly identified microorganisms. Levofloxacin 750 mg has shown equivalency to various non-fluoroquinolone regimens for the treatment of NAP and SSSI. Furthermore, a short, 5-day course of levofloxacin 750 mg was similar in efficacy to a longer, 10-day course of levofloxacin 500 mg for the treatment of CAP. Adverse events associated with levofloxacin therapy are dose independent; therefore, the adverse effects seen with high-dose levofloxacin are comparable to lower doses.
Conclusions
The levofloxacin 750 mg dosage formulation is a logical option when evaluating the antimicrobial armamentarium commonly utilized for the empiric treatment of CAP, NAP, and SSSI. Pharmacodynamic parameters are optimized and resistance is minimized when high-dose, short-course therapy is implemented.
YooB.K., TrillerD.M., YongC.S., LodiseT.P.Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Ann Pharmacother.2004; 38: 1226–1235.
2.
MartinS.J., JungR., GarvinC.G.A risk-benefit assessment of levofloxacin in respiratory, skin, and skin structure, and urinary tract infections.Drug Saf.2001; 24(3): 199–222.
3.
AndrioleV.T., ed. The Quinolones.3rd ed.San Diego, CA: Academic Press; 2000.
4.
CroomK.F., GoaK.L.Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.Drugs.2003; 63(24): 2769–2802.
KollefM.H., ShermanG., WardS., FraserV.J.Inadequate antimicrobial treatment of infections.Chest.1999; 115: 462–474.
8.
IreguiM., WardS., ShermanG., FraserV.J., KollefM.H.Clinical importance of the delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.Chest.2002; 122: 262–268.
CraigW.A.Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.Clin Infect Dis.1998; 26: 1–12.
11.
PeaF., FurlanutM.Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.J Chemother.2004; 16(suppl 2): 8–10.
12.
PrestonS.L., DrusanoG.L., BermanA.L.Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.JAMA.1998; 277(2): 125–129.
13.
DrusanoG.L., PrestonS.L., FowlerC.L., CorradoM., WeisingerB., KahnJ.Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.J Infect Dis.2004; 189: 1590–1597.
14.
ChienS.C., WongF.A., FowlerC.L.Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-gram doses of levofloxacin in healthy volunteers.Antimicrob Agents Chemother.1998; 42(4): 885–888.
15.
ChowA.T., ChenA., LattimeH.Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.J Clin Pharm Ther.2002; 27: 143–150.
16.
DrusanoG.L., PrestonS.L., GotfriedM.H., DanzigerL.H., RodvoldK.A.Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation.Antimicrob Agents Chemother.2002; 46(2): 586–589.
17.
Kaemmerer W: Levofloxacin. In: KlascoRK, ed: DRUGDEX System.Thomson MICROMEDEX, Greenwood Village, CO (Edition expired September, 2004).
18.
HobanD.J., BiedenbachD.J., MutnickA.H., JonesR.N.Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000).Diagn Microbiol Infect Dis.2003; 45: 279–285.
ListerP.D.Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumonia.Diagn Microbiol Infect Dis.2002; 44: 43–49.
WenzlerS., Schmidt-EisenlohrE., DaschnerF.Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.Chemotherapy.2004; 50: 40–42.
23.
MilatovicD., SchmitzF.J., BrisseS., Ve rhoefJ., FluitA.C.In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8796 clinical bacterial isolates.Antimicrob Agents Chemother.2000; 44(4): 1102–1107.
24.
WenzelR.P., SahmD.F., ThornsberryC., DraghiD.C., JonesM.E., KarlowskyJ.A.In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy.Antimicrob Agents Chemother.2003; 47(10): 3089–3098.
25.
JonesR.N., SaderH.S., BeachM.L.Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18,569 strains of non-fermentative gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).Int J Antimicrob Agents.2003; 22: 551–556.
26.
GaynesR., RimlandD., KillumE.Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.Clin Infect Dis.2004; 38: 640–645.
27.
GerdingD.N.Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem.Clin Infect Dis.2004; 38: 646–648.
28.
KoethL.M., GoodC.E., AppelbaumP.C.Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to coamoxiclav and five other antimicrobial agents.J Antimicrob Chemother.2004; 53: 1039–1044.
29.
DalhoffA., SchmitzF.J.In vitro antibacterial activity and pharmacodynamics of new quinolones.Eur J Clin Microbiol Infect Dis.2003; 22: 203–211.
30.
AkasakaT., TanakaM., YamaguchiA., SatoK.Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme mechanism of fluoroquinolone resistance.Antimicrob Agents Chemother.2001; 45(8): 2263–2268.
31.
HigginsP.G., FluitA.C., MilatovicD., VerhoefJ., SchmitzF.J.Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa.Int J Antimicrob Agents.2003; 21: 409–413.
32.
LowD.E.Quinolone resistance among pneumococci: therapeutic and diagnostic implications.Clin Infect Dis.2004; 38(suppl 4): S357–S362.
33.
BrownS.D., RybakM.J.Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.J Antimicrob Chemother.2004; 54(suppl 1); i7–i15.
34.
rownS.D., FarrellD.J.Antimicrobial susceptibility among Streptococcus pneumoniae isolated from pediatric and adult patients as part of the PROTEKT US study in 2001-2002.J Antimicrob Chemother.2004; 54(suppl 1); i23–i29.
35.
DunbarL.M., WunderinkR.G., HabibM.P., SmithL.G., TennenbergA.M., KhashabM.M.High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.Clin Infect Dis.2003; 37: 752–760.
36.
WestM.W., BoulangerB.R., FogartyC.Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia.Clin Ther.2003; 25(2): 485–506.
37.
GrahamD.R., TalanD.A., NicholsR.L.Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections.Clin Infect Dis.2002; 35: 381–389.
38.
DunbarL.M., KhashabM.M., KahnJ.B., ZadeikisN., XiangJ.X., TennenbertA.M.Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.Curr Med Res Opin.2004; 20(4) 555–563.
